Expert discussion: Latest frontline treatments
Leading lymphoma: Expert insights
Drs Stephen Ansell (USA), Pier Luigi Zinzani (Italy), and John Kuruvilla (Canada) discuss the latest frontline lymphoma treatments, including emerging data from this year’s congresses.
Hear about:
- The latest frontline therapies for classical Hodgkin, peripheral T-cell, and diffuse large B-cell lymphomas, with a focus on systemic advanced disease and how to balance traditional treatments with emerging options
- The shifting trend towards chemotherapy-free regimens, and expert guidance on using bispecific antibodies for specific patient subgroups
- Recent developments in chimeric antigen receptor (CAR) T-cell therapy and allogeneic stem cell transplants
- Key findings from STARGLO, HD21, and ECHELON, and their implications for clinical practice
Faculty
Dr Stephen Ansell
Stephen M Ansell, MD, PhD, is a consultant in the Division of Hematology, Department of Internal Medicine at Mayo Clinic in Minnesota, USA. Dr Ansell currently serves as chair of the Division of Hematology and the Enterprise Deputy Director of the Mayo Clinic Cancer Center. He joined the staff of Mayo Clinic in 1999 and holds the academic rank of Professor of Medicine, Mayo Clinic College of Medicine and Science.
Disclosures: Funding for research and clinical trials received from ADC Therapeutics, Affimed, AstraZeneca, Bristol Myers Squibb, Pfizer, Regeneron, and Takeda.
Dr Pier Luigi Zinzani
Pier Luigi Zinzani, MD, PhD, is Professor in the Department of Medical and Surgical Sciences at the University of Bologna, Italy, specialising in haematology with a focus on lymphomas and chronic lymphocytic leukaemia. Dr Zinzani is a member of various professional societies, including the Italian Society of Hematology, the American Society of Hematology, and the American Society of Clinical Oncology. His research primarily revolves around Hodgkin lymphoma, non-Hodgkin lymphoma, and hairy cell leukaemia, significantly advancing the field of haematologic malignancies.
Disclosures: Consultant for Bristol Myers Squibb, EUSA PHARMA, Kyowa Kirin, Novartis, Roche, Secura Bio, Servier, and Takeda. Member of the speakers’ bureau for AstraZeneca, Celltrion, EUSA PHARMA, Gilead, Janssen-Cilag, MSD, Novartis, Roche, and Takeda. Member of the advisory board for ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Celltrion, EUSA PHARMA, Gilead, Incyte, Janssen-Cilag, Kyowa Kirin, MSD, Novartis, Roche, Secura Bio, Servier, and Takeda.
Dr John Kuruvilla
John Kuruvilla, MD, FRCPC, is Professor of Medicine at the University of Toronto and a haematologist in the Division of Medical Oncology and Hematology at the Princess Margaret Cancer Centre (PM) in Toronto, Canada. He is a member of the Lymphoma, Autologous Transplant and Immune Effector Cell Therapy programmes. He is also the Co-Director of the High Definition Therapeutics Strategic Pillar for PM.
Disclosures: Honoraria from AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Genmab Gilead, Incyte, Janssen, Karyopharm, Merck, Novartis, Pfizer, Roche, and Seagen. Research support from AstraZeneca, Canadian Cancer Society Research Institute (CCSRI), Canadian Institutes of Health Research (CIHR), Kite, Leukemia and Lymphoma Society Canada, Merck, Novartis, and Princess Margaret Cancer Foundation. Consultant for AbbVie, Bristol Myers Squibb, Gilead/Kite, Merck, Roche, Seagen. Scientific advisory board: Lymphoma Canada (Chair). Data safety monitoring board: Karyopharm.